CARA
$15.89
Cara Therapeutics
($.07)
(.44%)
CARA
Earnings Whisper ®
N/A
1st Quarter March 2017
Consensus:  ($0.76)
Revenue:  $0.13 Mil
Thursday
May 4
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CARA reports earnings?
Beat
Meet
Miss

Where is CARA's stock price going from here?
Up
Flat
Down
Stock chart of CARA
Analysts
Summary of analysts' recommendations for CARA
Score
Grade
Pivots
Resistance
$16.78
$16.55
$16.22

$15.99

Support
$15.66
$15.43
$15.10
Tweet
Growth
Description
Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.
Peers
Johnson & JohnsonEli LillyRegeneron PharmaceuticalsBioMarin PharmaceuticalCelgeneVertex PharmaceuticalsEndo International plcPfizerBristol-Myers SquibbInterCept